Normotensive and Hypertensive Placental Abruptions

NCT ID: NCT04449601

Last Updated: 2020-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

115 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placental abruption is a significant cause of both maternal morbidity and neonatal morbidity and mortality. Most abruptions accept to be related to a chronic placental disease process. Therefore, it is very important to understand these processes. To analyze maternal and neonatal effects of placental abruption(PA) through a novel classification in the presence of hypertension. Initial hemoglobin parameters were also compared to predict pregnancy outcomes in addition to hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: We aimed to classify placental abruption according to hypertension status.

Methods: This retrospective cohort designed study was conducted on 115 pregnant women with placental abruption. The main parameters scanned and recorded from the hospital database and patient medical files. Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive). Maternal demographical and clinical characteristics (abdominal pain, vaginal bleeding) were recorded. APGAR scores below 5 at 1 and 5 min., fetal or neonatal death, admission and length of stay in Neonatal Intensive Care Unit(NICU) were also investigated and compared between the groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abruptio Placentae; Affecting Fetus or Newborn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (with hypertension )

Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).

clinical assesment

Intervention Type OTHER

Comparison of Hypertensive group and normotensive group

Group 2( without hypertension)

Two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive).

clinical assesment

Intervention Type OTHER

Comparison of Hypertensive group and normotensive group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clinical assesment

Comparison of Hypertensive group and normotensive group

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* spontaneous,
* singleton pregnancies
* above 25 weeks of gestations with positive fetal cardiac activity

Exclusion Criteria

* multiple gestations,
* presence of fetal or maternal infection,
* chronic inflammatory diseases or connective tissue disorders
* history of myocardial infarction,
* thrombosis
* history of steroid drug usage.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hatice Akkaya

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hatice Akkaya

Associate Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hatice Akkaya, Ass Prof

Role: PRINCIPAL_INVESTIGATOR

Kayseri Education and Research Hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E52332816/49

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Uterotonics for Severe Preeclampsia
NCT04756661 COMPLETED NA
Blood Loss and Preeclampsia
NCT04777097 RECRUITING